BR112018003127A2 - purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes - Google Patents
purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantesInfo
- Publication number
- BR112018003127A2 BR112018003127A2 BR112018003127A BR112018003127A BR112018003127A2 BR 112018003127 A2 BR112018003127 A2 BR 112018003127A2 BR 112018003127 A BR112018003127 A BR 112018003127A BR 112018003127 A BR112018003127 A BR 112018003127A BR 112018003127 A2 BR112018003127 A2 BR 112018003127A2
- Authority
- BR
- Brazil
- Prior art keywords
- fkpa
- methods
- bacteria
- purification
- multispecific antibodies
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 238000000746 purification Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 2
- 102000003813 Cis-trans-isomerases Human genes 0.000 abstract 1
- 108090000175 Cis-trans-isomerases Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000012434 mixed-mode chromatography Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207910P | 2015-08-20 | 2015-08-20 | |
| US201562207908P | 2015-08-20 | 2015-08-20 | |
| US201562210378P | 2015-08-26 | 2015-08-26 | |
| PCT/US2016/047912 WO2017031476A2 (en) | 2015-08-20 | 2016-08-19 | Purification of fkpa and uses thereof for producing recombinant polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018003127A2 true BR112018003127A2 (pt) | 2018-09-25 |
Family
ID=58052052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018003127A BR112018003127A2 (pt) | 2015-08-20 | 2016-08-19 | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180327446A1 (enExample) |
| EP (1) | EP3337819B1 (enExample) |
| JP (2) | JP7091238B2 (enExample) |
| KR (1) | KR20180048731A (enExample) |
| CN (1) | CN108473558A (enExample) |
| AU (1) | AU2016308383A1 (enExample) |
| BR (1) | BR112018003127A2 (enExample) |
| CA (1) | CA2995385A1 (enExample) |
| HK (1) | HK1259368A1 (enExample) |
| IL (2) | IL257400A (enExample) |
| MX (1) | MX2018002068A (enExample) |
| TW (1) | TW201718623A (enExample) |
| WO (1) | WO2017031476A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| JP7410860B2 (ja) * | 2017-12-29 | 2024-01-10 | エフ． ホフマン－ラ ロシュ アーゲー | Ｐｅｇ化タンパク質組成物を提供するための方法 |
| US12208142B2 (en) | 2017-12-29 | 2025-01-28 | Hoffmann-La Roche Inc. | Process for providing PEGylated protein composition |
| BR112020015603A2 (pt) * | 2018-02-27 | 2021-01-05 | Pfizer Inc. | Purificação de anticorpo |
| SG11202009213TA (en) * | 2018-03-21 | 2020-10-29 | Baxalta Inc | Separation of vwf and vwf propeptide by chromatographic methods |
| EP3774926A1 (en) | 2018-04-05 | 2021-02-17 | Bio-Rad ABD Serotec GmbH | Display systems for proteins of interest |
| US20220034899A1 (en) * | 2018-09-25 | 2022-02-03 | Ichnos Sciences S.A. | Antibody quantification in biological samples |
| CN114409798A (zh) * | 2019-02-14 | 2022-04-29 | 美勒斯公司 | 制备包含两种或更多种抗体的组合物 |
| EP3942079A1 (en) | 2019-03-18 | 2022-01-26 | Bio-Rad ABD Serotec GmbH | Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation |
| AU2020268896B2 (en) * | 2019-05-03 | 2024-11-28 | F. Hoffmann-La Roche Ag | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
| AR120794A1 (es) * | 2019-12-20 | 2022-03-16 | Merck Sharp & Dohme | Composiciones purificadas de enterovirus y métodos de purificación con cromatografía de afinidad con glutatión |
| BR112022016598A2 (pt) * | 2020-02-21 | 2022-11-08 | Biogen Ma Inc | Métodos de preparação de composições de oligonucleotídeo utilizando ultrafiltração/diafiltração |
| US20230357315A1 (en) * | 2020-03-11 | 2023-11-09 | Dr. Reddy's Laboratories Limited | METHOD OF PURIFYING AN Fc-FUSION PROTEIN |
| EP4408856A4 (en) * | 2021-09-28 | 2025-11-12 | Kashiv Biosciences Llc | IMPROVED PROCESS FOR PROTEIN PURIFICATION |
| CN118284809A (zh) * | 2021-11-25 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 少量抗体副产物的定量 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1356052T3 (da) * | 2000-12-14 | 2008-12-08 | Genentech Inc | Produktion af hele antistoffer i prokaryotiske celler |
| NZ588674A (en) * | 2008-05-05 | 2013-02-22 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| CN105111309A (zh) * | 2008-10-20 | 2015-12-02 | Abbvie公司 | 使用a蛋白亲和层析分离和纯化抗体 |
| MX341136B (es) * | 2009-10-20 | 2016-08-09 | Abbvie Inc | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a. |
| US9096648B2 (en) * | 2011-08-19 | 2015-08-04 | Emd Millipore Corporation | Methods of reducing level of one or more impurities in a sample during protein purification |
| BR112014011900A2 (pt) * | 2011-12-15 | 2017-05-16 | Hanwha Chemical Corp | um método de purificação de anticorpo |
| TW201333035A (zh) * | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| EP2943568B1 (en) * | 2013-01-09 | 2019-11-20 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase a |
| EP2981286A4 (en) * | 2013-04-05 | 2016-08-24 | Hoffmann La Roche | ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF |
| KR102289258B1 (ko) * | 2013-04-19 | 2021-08-11 | 서트로 바이오파마, 인크. | 상승된 수준의 외인성 샤페론을 갖는 세포 추출물을 이용한 박테리아 세포 비함유 합성 시스템에서의 생물학적 활성 단백질의 발현 |
| MX2016001601A (es) * | 2013-08-19 | 2016-05-02 | Hoffmann La Roche | Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita. |
| KR102571391B1 (ko) * | 2013-09-13 | 2023-08-29 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
| US20160272673A1 (en) * | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of dvd-igs |
| MX2016010729A (es) * | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
-
2016
- 2016-08-19 WO PCT/US2016/047912 patent/WO2017031476A2/en not_active Ceased
- 2016-08-19 CA CA2995385A patent/CA2995385A1/en not_active Abandoned
- 2016-08-19 CN CN201680061356.3A patent/CN108473558A/zh active Pending
- 2016-08-19 TW TW105126681A patent/TW201718623A/zh unknown
- 2016-08-19 BR BR112018003127A patent/BR112018003127A2/pt not_active IP Right Cessation
- 2016-08-19 HK HK19101736.6A patent/HK1259368A1/zh unknown
- 2016-08-19 AU AU2016308383A patent/AU2016308383A1/en not_active Abandoned
- 2016-08-19 KR KR1020187007920A patent/KR20180048731A/ko not_active Ceased
- 2016-08-19 EP EP16758343.4A patent/EP3337819B1/en active Active
- 2016-08-19 MX MX2018002068A patent/MX2018002068A/es unknown
- 2016-08-19 JP JP2018509536A patent/JP7091238B2/ja active Active
-
2018
- 2018-02-07 IL IL257400A patent/IL257400A/en unknown
- 2018-02-16 US US15/932,222 patent/US20180327446A1/en not_active Abandoned
-
2021
- 2021-11-17 IL IL288205A patent/IL288205A/en unknown
-
2022
- 2022-01-13 JP JP2022003518A patent/JP2022062046A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016308383A1 (en) | 2018-03-15 |
| WO2017031476A2 (en) | 2017-02-23 |
| EP3337819C0 (en) | 2024-02-21 |
| IL288205A (en) | 2022-01-01 |
| HK1259368A1 (zh) | 2019-11-29 |
| JP2018533355A (ja) | 2018-11-15 |
| CA2995385A1 (en) | 2017-02-23 |
| WO2017031476A3 (en) | 2017-04-13 |
| MX2018002068A (es) | 2018-06-06 |
| JP2022062046A (ja) | 2022-04-19 |
| US20180327446A1 (en) | 2018-11-15 |
| KR20180048731A (ko) | 2018-05-10 |
| CN108473558A (zh) | 2018-08-31 |
| EP3337819A2 (en) | 2018-06-27 |
| EP3337819B1 (en) | 2024-02-21 |
| TW201718623A (zh) | 2017-06-01 |
| JP7091238B2 (ja) | 2022-06-27 |
| IL257400A (en) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| ZA202308519B (en) | Anti-vegf protein compositions and methods for producing the same | |
| BR112018004965A2 (pt) | domínios de superfamìlia de imunoglobulina variante ajustàvel | |
| BR112018070934A2 (pt) | proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas | |
| BR112018075516A2 (pt) | purificação de anticorpos multiespecíficos | |
| BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
| WO2017024317A3 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
| BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| EA201990317A1 (ru) | Способы определения количества индивидуальных антител из смеси | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
| CL2015002655A1 (es) | Moduladores de p2x7 | |
| BR112012017124B8 (pt) | método para produzir e para purificar um multímero polipeptídico | |
| BR112022008092A2 (pt) | Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico | |
| MX372711B (es) | Metodos para la purificacion de arilsulfatasa a. | |
| SG10201902850TA (en) | Human-derived anti-dipeptide repeats (dprs) antibody | |
| EA201690958A1 (ru) | Депрессанты для применения в способах разделения | |
| BR112017001417A2 (pt) | variantes de proteína de ligação ao fator h e métodos para uso das mesmas | |
| CL2018002769A1 (es) | Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso. | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| TW201613981A (en) | Compositions and methods for the diagnosis of rheumatoid arthritis | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2736 DE 13-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |